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comorbidities. She had ERCP with stent insertion and
papillotomy for a bile duct that was impacted with gallstones.
Dozens of stones were removed endoscopically at that time;
however, a second ERCP was performed due to recurrent
jaundice and symptoms. The first stent had migrated and the
duct was still impacted despite removing even more stones.
She was referred for laparoscopic common bile duct explo-
ration. This video demonstrates all of the steps required for
total clearance of the common duct in a challenging case:
duct exposure, choledochotomy, stone and stent extraction,
complete choledochoscopy and stone extraction, duct
closure, cholecystectomy, and cholangiography. A T-tube
was not inserted at the conclusion of the operation as the
patient had a recent papillotomy and her anatomy was normal
(no Roux-en-Y).
CV-B.05 LAPAROSCOPIC PARTIAL
SLEEVE DUODENECTOMY (PSD) FOR
DUODENAL ADENOMA
J. A. Stauffer and H. J. Asbun
Mayo Clinic, Jacksonville, FL
The video submission is a case presentation of a 65-year-old
female who was found to have a circumferential adenoma of
the infra-ampullary duodenum. She was taken to surgery and
underwent a laparoscopic partial sleeve duodenectomy
(PSD). The video shows technical considerations and steps
of laparoscopic PSD. Laparoscopic PSD spares resection of
the head of the pancreas by separating the duodenum from
the head of the pancreas under direct magnified vision.
Intraoperative upper endoscopy was performed to ensure
complete adenoma removal and patency of the ampulla prior
to transection of the duodenum just distal to the ampulla.
Reconstruction was performed with a side to side
duodenojejunostomy. The patient was found to have a 5-cm
tubulovillous adenoma with high grade dysplasia and recov-
ered without any complications.
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MO-A.01 OVERALL SURVIVAL BY
PATTERN OF RECURRENCE
FOLLOWING CURATIVE INTENT
SURGERY FOR COLORECTAL LIVER
METASTASIS
A. N. Kulaylat, J. R. Schubart, A. L. Stokes, E. T. Kimchi,
K. F. Staveley-O’Carroll, N. J. Bhayani, J. T. Kaifi and
N. J. Gusani
Section of Surgical Oncology, Penn State Hershey Cancer
Institute, Hershey, PA
Introduction: Following curative intent surgery (CIS) for
colorectal liver metastasis (CRLM), patterns of recurrence
and subsequent survival outcomes are not widely reported.
Methods: An institutional database (January 2002-
December 2012) was reviewed to evaluate patterns of recur-
rence following CIS for CRLM.
Results: 183 patients with CRLM underwent CIS (liver
resection, ablation, or both). Median follow-up and
progression-free survival (PFS) was 28 and 16 months,
respectively. 5-year overall survival (OS) was 51%. After
initial CIS, 102 (56%) patients recurred: 44% liver (5-year
OS 55%), 15% lung (5-year OS 45%), and 41% other/
multifocal (5-year OS 20%). While OS for liver vs. lung was
not significantly different, both were better compared to
other/multifocal (p = 0.018 for liver vs. other, p = 0.086 for
lung vs. other). Wider liver resection margins reduced the
risk of general (RR 0.95, p = 0.018) and isolated liver (RR
0.93, p = 0.043) recurrence. Other/multifocal recurrence was
more likely with extrahepatic disease at time of liver resec-
tion (RR 7.83, p = 0.045) and bilateral liver metastasis (RR
3.61, p = 0.041), but less likely with staged resections
(RR 0.11, p = 0.016), and increasing liver resection margin
(RR 0.90, p = 0.012). Of 102 1st recurrences, 53 patients were
able to undergo repeat CIS (in 71% liver recurrences, 67%
lung, and 24% other/multifocal). When repeat CIS was pos-
sible, 5-yr OS was 67%.
Conclusion: Patients with liver- or lung-only recurrences
after CIS for CRLM have high rates of repeat CIS and excel-
lent survival. Repeat CIS offers improved survival and
should be pursued where possible.
MO-A.02 INTRA-OPERATIVE LIVER
BIOPSY PATHOLOGY IN PATIENTS
UNDERGOING WEIGHT LOSS SURGERY
A. Dan1,3, M. Subichin1,3, J. Clanton1,3, M. Makuszewski3,
A. Bohon3, M. Pozsgay1,3, R. Shenoy1, S. M. Thompson2,3,
A. Venkataramani4, C. Sievers4 and J. Zografakis1,3
1Summa Health System Department Of Surgery, Akron,
OH; 2Summa Health System Department Of Pathology,
Akron, OH; 3Northeast Ohio Medical University,
Rootstown, OH; 4Summa Health System Department Of
Gastroenterology, Akron, OH
Introduction: The incidence of liver disease in the morbidly
obese varies, but most studies to date are small series. To
determine the degree of liver pathology at the time of weight
loss surgery, liver biopsy is often performed. We sought to
review the utility of routine liver biopsy and determine the
frequency of abnormal liver pathology in a large sample of
morbidly obese patients.
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Methods: A retrospective chart review of 1,000 consecutive
patients undergoing weight loss surgery was performed. Data
collected included: age, sex, BMI, liver function tests and
liver biopsy pathology results. Student’s t-test was used to
compare groups.
Results: The average age of the study population was 48
years, with a 4 : 1 female to male ratio. All patients had a
BMI greater than 35 kg/m2. Of these patients, 81.2% had
liver pathology related to obesity seen on pathology, includ-
ing 70.3% with steatosis (Grade 1–3), and 4.6% with non-
alcoholic steatohepatitis (NASH). The mean BMI of patients
with steatosis was 47.7 compared to a BMI of 48.7 without
steatosis (p = 0.088). Mean BMI of patients with and without
NASH was 49.9 and 47.9, respectively (p = 0.11).
Conclusion: Significant liver pathology is highly prevalent
in the obese population, but is not statistically associated
with higher BMI. Pathologic examination is an excellent
modality to delineate and specify the extent of the disease.
This data represents the largest single center analysis of
consecutive liver biopsies of patients with morbid obesity.
Liver biopsy remains a valuable component in the treatment
of patients undergoing weight loss surgery.
MO-A.03 ALTERATIONS IN HIPPO
SIGNALING PATHWAY DURING LIVER
REGENERATION
J. Grijalva1, M. Huizenga2, F. Camargo1, G. Sadri-Vakili2,
K. Vakili1
1Boston Children’s Hospital, Boston, MASSACHUSETTS;
2Massachusetts General Hospital, Charlestown, MA
Background: The Hippo signaling pathway has been impli-
cated in organ size regulation and hepatocyte proliferation,
however, its role in liver regeneration (LR) is unclear. The
Hippo pathway modulates activity of the transcriptional
co-activator YAP which regulates a proliferative transcrip-
tional program. Phosphorylation of YAP (pYAP) results in its
degradation. Thus, we hypothesized that the Hippo pathway
modulates LR and we sought to characterize its signaling
alterations during LR.
Methods: 70% rat partial hepatectomy (PH) model was
used. Remnant livers were collected 1–30 days post-PH
(n = 4–8/group). Liver/body weight ratios were calculated.
Western blot analysis was performed on YAP, pYAP, Mst1
and phosphorylated Mst1. YAP target gene expression of
Cyr61 and AmotL2 was measured using RT-qPCR. Each
animal served as its own control.
Results: The liver/body weight ratio approached preoperative
levels 7 days post-PH. A Significant increase in total YAP was
observed 1–7 days post-PH (P < 0.05) followed by a significant
decrease in pYAP from days 3–14 (p = 0.045). A Significant
decrease in Hippo kinase Mst1 phosphorylation (a ctivated) was
observed 1–3 days post-PH (P < 0.05) (Figure 1). Significant
increase in Cyr61 (P < 0.005) and AmotL2 (P = 0.0167) mRNA
expression was observed 1–3 days post-PH.
Conclusions: Our findings demonstrate dynamic changes in
the Hippo pathway following PH that stabilize when liver/
body weight ratio reaches normal levels. Additionally, our
findings demonstrate increased levels of active YAP and
increased YAP target gene expression during LR. These
results suggest that this pathway may be an important mecha-
nism underlying hepatocyte proliferation during LR and
provide a potential therapeutic target to enhance LR.
MO-A.04 VALIDATION OF THE
SELECTION CRITERIA FOR SAFE
HEPATECTOMY FOR
HEPATOCELLULAR CARCINOMA:
ANALYSIS OF 312 CONSECUTIVE
HEPATECTOMIES
M. Donadon, F. Procopio, M. Cimino, G. Costa,
D. Del Fabbro, A. Palmisano, A. Gatti and G. Torzilli
Liver Surgery Unit, Department of General Surgery,
Humanitas Clinical And Research Center, Rozzano, MiLAN
Introduction: Hepatectomy is the treatment of choice for
hepatocellular carcinoma(HCC). The estimation of func-
tional liver reserve is the stronghold to achieve good results.
The aim of this study was the validation of the selection
criteria for safe hepatectomy for HCC.
Methods: Clinical, pathological and short-term data were
reviewed in a prospective cohort of patients who underwent
hepatectomy between 2004–2013. All consecutive patients
were submitted to hepatectomy based on the same selection
criteria, which included bilirubin(BIL), cholinesterases
(CHE), the presence of ascites, the presence of esophageal
varices, and the residual liver volume. Univariate, and mul-
tivariate analyses were performed.
Results: A total of 312 patients were analyzed. One hundred
three patients (33%) had thoracoabdominal approach, but
only 36 (12%) had major or extended resections. The median
tumor number was 1(range 1–33), while the median tumor
size was 4,5 cm (range 0.8–28). BCLC were 0-A in 53%, B
in 25%, and C in 22%. Of those patients, 94 (29%) had
complications, of which 6% were major(Dindo > IIIa). The
30- and 90-days mortality were 1.2 % and 1.8% respectively.
The MELD, APRI, and CPT-scores were tested. None of
these were found to be statistically significant at the logistic
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regression analysis, while the use of the combination of
BIL > 1 and CHE≤5.900 was the best combination to detect
complications (P = 0.007), and specifically liver-related
complications such as ascites (P = 0.000).
Conclusions: This study shows that our selection criteria
that counts mainly on two simple, fast, and cheap parameters,
BIL and CHE, lead to identify patients potentially at risk of
complications after hepatic resection for HCC.
MO-A.05 READMISSION AFTER
HEPATIC RESECTION AT A
QUATERNARY ACADEMIC CENTER
A. Ejaz, G. Spolverato, D. Lucas, M. Weiss, C. Wolfgang,
K. Hirose, M. Choti and T. M. Pawlik
Johns Hopkins Hopsital, Baltimore, MD
Introduction: Reducing readmission has become a key
quality improvement target for policymakers. We sought to
define the incidence and identify factors associated with
readmission after hepatic resection at a quaternary academic
center.
Method: Readmission within 30 days of discharge after
hepatic resections between 2008 and 2012 at a major aca-
demic center was analyzed. Modified Poisson regression
with a robust variance estimator was used to calculate risk
ratios for readmission.
Results: Among 357 patients indications for surgery
included colorectal liver metastasis(42.6%), non-colorectal
liver metastasis(35.3%), primary hepatic tumors(17.7%), and
benign disease(2.8%). Comorbidities were common: 74.2%
were ASA class 3–4. Operations included non-anatomic
resection(69.5%), hemi-hepatectomy(17.1%), and
trisegmentectomy(12.9%). Median length-of-stay was 5
days; 48.2% patients experienced at least one inpatient com-
plication. Overall 30-day readmission was 11.8%(n = 42); an
additional 4(1.1%) patients died at home within 30-days.
Causes of readmission included abdominal infection(40.5%),
liver dysfunction (7.1%), other gastrointestinal complica-
tion(31.0%), venous thromboembolism(7.1%), pulmonary
complication(4.8%), and other(11.9%). Median length-of-
stay for the readmission was 4 days. Factors associated with
readmission included preoperative weight loss(RR-2.38,
95% CI 1.35–4.18), MELD score of >10(RR-2.26, 95% CI
1.10–4.64), ICU length-of-stay >1 day(RR-2.02, 95% CI
1.14–3.58), total length-of-stay >5 days(RR-2.60, 95%
CI 1.39–4.83), and any inpatient complication(RR-1.94, 95%
CI 1.07–3.52)(all P < 0.05). On multivariable analysis, the
strongest predictor of readmission was length-of-stay >5
days (adjusted RR-2.30, 95% CI 1.24–4.28, p = 0.009)
(Figure).
Conclusion: Readmission after hepatic resection occurred
in roughly 1 in 10 patients. Risk of readmission was associ-
ated with patient- (weight loss, MELD score), surgical-
(history of complication) and hospital- (length of stay) level
factors.
MO-A.06 QUALITY OF LIFE AFTER
RESECTION OF INTRA- AND
EXTRA-HEPATIC METASTASES FROM
COLORECTAL ADENOCARCINOMA IN A
MULTI-CENTER PROSPECTIVE PHASE
II TRIAL
P. E. SErrano1, N. G. Coburn2, K. S. Devitt1, C. Moulton1,
S. P. Cleary1, C. Law2, P. D. Greig1, S. Gallinger1 and
A. C. Wei1
1Hepatobiliary And Surgical Oncology, Toronto, ON;
2Hepatobiliary And Surgical Oncology, Toronto, ON
The concept of combined resection of intra- and extra-
hepatic metastases (IHM and EHM) from colorectal cancer
(CRC) is evolving. This study evaluated the quality of life
(QOL) of patients with IHM and EHM from CRC undergo-
ing complete metastasectomy.
Methods: Participants of a Phase-II multi-institutional trial
with any number of CRC IHM and up to 3 foci of EHM,
resectable with RO intent completed QOL questionnaires
(EORTC-QLQ-C30, EORTC-LMC 21 and FACT-Hep) at
baseline, prior to surgery and at 4-8-12 months following
complete metastasectomy. Mean scores were compared to
baseline. Change >10% was considered a minimally impor-
tant clinical difference (MICD).
Results: There were 25 participants. Median disease-free
survival was 6 (0–17) months. EORTC-QLQ-C30 global-
QOL remained statistically and clinically unchanged com-
pared to baseline at 4 and 8 months but had a clinically
significant decline at 12 months (−15.3, P = 0.25). FACT-
Hep Total (−8.3, P = 0.03) and Trial Outcome Index (−6,
P = 0.03) score were statistically lower at 4 months post
surgery, without reaching a MICD. At this time-point there
was a transient increase in fatigue (+17.7, P = 0.004), appe-
tite loss (+12.8, P = 0.02) and a decrease in social (−22.4,
P = 0.004) and role (−12.6, P = 0.002) functioning. All
subscales returned to baseline levels at 12 months.
Conclusions: Despite early disease recurrence after aggres-
sive metastasectomy of multi-site CRC, there was no signifi-
cant deterioration of global QOL as a result of treatment.
There was a transient increase in symptoms (fatigue and loss
of appetite) and a decrease in functioning scores (role and
social) at 4 months from surgery, improving by 12 months.
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MO-A.07 INTRAOPERATIVE
ULTRASOUND AND SURGICAL
STRATEGY IN HEPATIC RESECTION:
WHAT DIFFERENCE DOES IT MAKE?
R. Jrearz1, R. S. Hart1,2 and S. Jayaraman1,2
1Division Of General Surgery, University Of Toronto,
Toronto, ON; 2HPB Service, St. Joseph’s Health Centre,
Toronto, ON
With modern advancements in preoperative imaging for liver
surgery, intraoperative ultrasound (IOUS) may be perceived
as superfluous. Our aim was to determine if IOUS provides
new information that changes surgical strategy in hepatic
resection. From a single institution, 111 consecutive patients
who underwent 121 liver resections were analyzed. Preop-
erative CT and/or MRI determined the surgical strategy.
Comparisons between the number, size, and location of
lesions were compared between IOUS and preoperative
imaging. Reasons for changes in surgical strategy were docu-
mented. Pathology reports were analyzed for margins. Con-
tinuous variables were compared using parametric t-tests and
categorical variables were compared using the chi square test
for independence. P-values of less than or equal to 0.05 were
considered statistically significant. IOUS was used in 88 of
121 procedures. IOUS changed the surgical plan in 17%
(n = 15) cases. Additional tumors were detected in 7% (6) of
cases. A change in size and location were detected in, 9% (8)
and 7% (6) of cases respectively. Surgical plans were
changed in 8% (7) cases for reasons not related to IOUS.
IOUS helped demarcate the resection plane in the remaining
75% (66) of cases. The average margin was 1.09 cm (1.18)
for IOUS and 1.18 cm (1.05) for non-IOUS. There were no
significant differences in margin length (p = NS) between the
groups. Surgical strategy was directly altered due to IOUS in
a substantial number of cases. IOUS guided resection planes
resulted in R0 resections in nearly all procedures. The best
operative plan in hepatic resection includes intraoperative
ultrasound.
MO-A.08 RELIABILITY, SAFETY AND
ONCOLOGICAL SUITABILITY OF
INTRAOPERATIVE ULTRASOUND
CRITERIA FOR HEPATIC VEINS
SPARING ONCE IN CONTACT WITH
COLORECTAL LIVER METASTASES AT
THE CAVAL CONFLUENCE:
VALIDATION ON AN INTENTION TO
TREAT ANALYSES
F. Procopio, M. Donadon, M. Cimino, D. Del Fabbro,
G. Costa, A. Gatti, A. Palmisano and G. Torzilli
University Of Milan-School Of Medicine, Humanitas
Clinical And Research Center, Rozzano, MILAN
Major-hepatectomies are generally selected for tumors in
contact/involving the hepatic-vein(HV) at caval confluence
(CC). Whenever a conservative approach is attempted,
HV-reconstruction is recommended. The use of criterion
based on intraoperative-ultrasonography (IOUS) may limit
the need for extensive hepatectomy. An intention-to-treat
prospective study to validate this hypothesis has been con-
ducted in a cohort of patients with at least one colorectal-
metastasis (CLM) in contact with a HV at CC. Thirty-eight
patients showing at preoperative imaging at least one CLM in
contact with a HV at CC were enrolled.Based on IOUS-
findings, 3 patterns of presentation were recognized and
respective surgical policies were established : Type-A : HV
in contact with CLM for <1/3 of its circumference, regardless
of longitudinal extension : vein-sparing with tumor-
detachment was planned; Type-B : HV-involvement ranging
1/3–2/3 of its circumference, regardless of longitudinal
extension : vein-sparing with HV wall-resection and recon-
struction by direct-suture or patching was planned;Type-
C : HV-involvement for ≥2/3 of its circumference with/
without interruption of vessel-wall at IOUS : vein-resection
was planned. At IOUS-exploration of the 38 patients, 25
included at least a Type-A contact, 13 Type-B, while 9
Type-C invasion. No major-hepatectomy was required.
Tumor-detachment from HV was feasible in 30 (79%)
patients, HV-reconstruction with direct-suture in 13 (34%),
while HV-resection was performed in 9 (23%). Postoperative
mortality was nil.Overall and major morbidity rate was 39%,
5%. No local-recurrences have been observed at a median
follow-up of 13 months (range 6–34). Preserving liver-
parenchyma in hepatectomy is the key-factor to ensure better
postoperative results. This proposed tumor-vessel classifica-
tion has been validated on an intention-to-treat perspective
and in all patients was able to predict the proper surgical
strategy. Adopting these criteria major-hepatectomies can be
avoided in favor of a surgical policy, which is safe and fea-
tured by acceptable oncological radicality.
MO-A.09 PREOPERATIVE PREDICTIVE
MODEL OF SURVIVAL AFTER
RESECTION FOR INTRAHEPATIC
CHOLANGIOCARCINOMA (IHCC)
A. Schneck1, D. Subar2, R. Memeo1, F. Vittore1,
P. Compagnon1, A. Laurent1 and D. Azoulay1
1Service De Chirurgie Digestive, APHP Henri Mondor
Hospital Créteil, VAL DE MARNE; 2Department Of
General And HPB Surgery, Blackburn Royal Hospital,
Blackburn, LANCASHIRE
Background: Patient survival with intrahepatic
cholangiocarcinoma (IHCC) after resection depends on
histopathological factors. One study has reported on preop-
erative predictive factors. This study assesses a preoperative
model in predicting survival of patients with IHCC who have
undergone curative resection.
Methods: This is a retrospective single institution study of
patients who had curative hepatic resection between Septem-
ber 1990 and December 2012 for IHCC. Preoperative factors
including patient sex, age, body mass index (BMI), perfor-
mance status (PS), serum bilirubin, serum alkaline phos-
phatase (ALP), CA19.9, tumour size and number of tumour
nodules on preoperative computed tomography (CT) were
converted to categorical variables and analysed. Significant
predictive factors on uni-and multivariate analysis was
scored as 0 or 1 based on cut-off value for each significant
variable and entered into a model.
Results: 78 patients had hepatic resection for IHCC. The
male to female ratio was 50 : 28 and mean age was 60 years.
The median survival was 12.2 months. Factors predictive of
survival in univariate and multivariate analyses were
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BMI > 30 kg/m2, ALP >115 IU/L, tumour size > 6 cm,
CA19.9 > 35 IU/ml and greater than 1 nodule present on
preoperative CT. Classification of patients based on a predic-
tive model using a score of 1 for low risk, 2–3 for intermedi-
ate risk and greater than 3 for high risk patients was
predictive of survival (p < 0.05).
Conclusion: Our model based on preoperative factors can
predict long term survival. The model needs to be validated
in a prospective trial and may help in patient selection for
surgical intervention.
MO-A.10 OUTCOMES OF
UNRESECTABLE SOLITARY
HEPATOCELLULAR CARCINOMAS
SIZED 5 TO 8 CM TREATED BY
RADIOFREQUENCY ABLATION VERSUS
TRANSARTERIAL
CHEMOEMBOLIZATION
W. Dai, T. Cheung and R. Poon
Department Of Surgery, The University Of Hong Kong,
Hong Kong, China, Pokfulam, NA
Objective: To compare the efficacy of radiofrequency abla-
tion (RFA) versus transarterial chemoembolization (TACE)
in treating large (5–8 cm) unresectable solitary hepatocellu-
lar carcinomas (HCCs).
Design: Retrospective study of prospectively collected data.
Setting: RFA and TACE as feasible options for treating
large solitary HCCs unresectable because of poor liver
reserve or other patient factors.
Patients and Intervention: Among 41 patients who had
large unresectable solitary HCCs, 15 patients received RFA
and 26 patients received TACE.
Main Outcome Measures: The primary endpoint was
overall survival and the secondary endpoints were tumor
response, time to disease progression, and treatment-related
morbidity and mortality.
Results: The complication rate was 33% in the RFA group
and 19.2% in the TACE group (P = 0.525). In the RFA group,
the complete ablation rate was 80% and local recurrence rate
6.7%, and the median disease-free survival was 13 (2.8–38)
months. In the TACE group, there was no complete response
whereas the partial response rate was 15.4%, and the median
time to disease progression was 8 (1–68) months. The RFA
group had a median survival duration of 39.8 months and that
in the TACE group was 19.75 months (P = 0.257). The 1-, 2-
and 5-year survival rates were 93.3%, 86.2% and 20.9%
respectively in the RFA group and 73.1%, 40.6% and 18.3%
respectively in the TACE group.
Conclusion: RFA resulted in better initial tumor control and
a higher short-term survival rate, but the two treatment
modalities brought about similar long-term survival.
MO-A.11 THE ASSOCIATION OF
HYPOPHOSPHATEMIA WITH
POST-HEPATETCTOMY LIVER FAILURE
AND RECOVERY
J. Hallet1, F. Zih2, J. Wong3, E. Cheng3, S. Hanna3,
P. Karanicolas3, N. Coburn3 and C. Law3
1Division Of Surgical Oncology, University Of Toronto,
Toronto, ONTARIO; 2Department Of General Surgery,
University Of Toronto, Toronto, ONTARIO; 3Division Of
Surgical Oncology, Sunnybrook Health Sciences Centre,
Toronto, ONTARIO
Introduction: Hypophosphatemia is frequent following
hepatectomy and thought to represent phosphate use during
liver regeneration. Its association with postoperative liver
function remains controversial. We sought to evaluate the
association of post-hepatectomy hypophosphatemia with
liver failure and recovery.
Methods: Four hundred liver resections were retrospectively
reviewed from 2003 to 2013 at a single institution. Primary
outcome was occurrence of liver failure (“50/50” criteria).
Secondary outcomes were liver recovery at discharge, 30-day
morbidity according to Clavien-Dindo classification, and
30-day mortality. Outcomes of clinically significant post-
hepatectomy hypophosphatemia cases (HP [≤0.65 mmol/L])
were compared to non-hypophosphatemia controls (NHP).
Results: 320 (80.0%) patients experienced HP. Liver failure
occurred significantly more often with HP than NHP (19.7%
Vs. 11.2%, p0.02). However, we observed a trend towards
less liver failure at discharge in HP (1.7% Vs. 4.3%, p0.20).
Length of stay, Clavien-Dindo complications, and mortality
were similar. 82.0% of liver failures recovered before dis-
charge. More patients who recovered experienced HP com-
pared to those who did not (70.7% Vs. 11.1%, p < 0.01).
Demographics, diagnosis and extent of surgery did not differ
between hypophosphatemia or recovery groups.
Conclusion: Post-hepatectomy HP is associated with
increased incidence of liver failure, but not increased mor-
bidity or mortality. HP occurred more often in patients who
recovered, highlighting efficient liver regeneration. Further
studies should explore the usefulness of the trend of phos-
phate drop for early identification of patients likely to recover
fast from liver failure.
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MO-A.12 VALIDATION OF OUR POLICY
OF LONG-TERM DRAINS
MAINTENANCE AFTER HEPATIC
RESECTION: RESULTS OF A
PROSPECTIVE COHORT ANALYSIS
M. Donadon, G. Costa, F. Procopio, M. Cimino,
D. Del Fabbro, A. Palmisano, A. Gatti and G. Torzilli
Liver Surgery Unit, Department Of General Surgery,
Humanitas Clinical and Research Center, Rozzano, MILAN
Background: The utility of drains after hepatic resection is
debated. The aim of this study was the validation of our
definition, and management of biliary fistula after hepatic
resection. We also reviewed the literature, in particular the
definition by the International Study Group of Liver
Surgery(ISGLS).
Methods: Data on abdominal drains and on clinical, patho-
logical and short-term outcome were reviewed in a prospec-
tive cohort of patients who underwent hepatic resection
between 2004–2013. Drains were maintained at least 7 days,
and the bilirubin levels were measured in POD3, 5, and 7.
Drains were removed if the bilirubin level in POD7 was
inferior than in POD5, and less than 10 mg/dl. Statistical
analysis on prognostic factors for biliary fistula was
performed.
Results: Among 475 consecutive patients, 39 (8%) had
biliary fistulas. Only 8 (1.7%) patients required
interventional procedures. The area under the receiver-
operating-characteristic curve on POD7 had the highest pre-
dictive value(0.81, p < 0.001). The multivariate analysis
found a protective role for cirrhosis (OR = 0.56 = ,
p = 0.045), while a Pringle’s maneuver >90 minutes
(OR = 3.45, p < 0.001), extended resections (OR = 6.45,
p = 0.007), blood transfusions (OR = 2.4, p = 0.035), and
resections including segment-I (OR = 1.94, p = 0.033), and
segment-V (OR = 1.87, p = 0.024) were found to be associ-
ated with increased risk. Using the definition proposed by the
ISGLS 66% of our patients would have received a diagnosis
of biliary fistula.
Conclusions: The maintenance of abdominal drains up to
POD7 reduces the risk of biliary fistulas after hepatic resec-
tion. The greater is the complexity of hepatic resection the
greater is the risk of biliary fistula, which may effectively
managed with drains maintenance.
MO-A.13 LIVER CANCER IN TEXAS:
ENVIRONMENTAL RISK FACTORS
CONTRIBUTING TO HIGHER
INCIDENCE RATE
D. Zorzi1, G. Curcuru’2, C. Rhoads1, V. Gazis1,
C. Rastellini1 and L. Cicalese1
1UTMB, Galveston, TX; 2University Of Palermo, Palermo,
PA
Introduction: Incidence rate for primary liver cancer (LK)
in Texas is rising and above US rate (9.3 vs. 6.7, respectively
in 2010). Texas has the largest oil and gas industry and is the
second largest agricultural producer. No population-based
studies are available investigating Hazard Air Pollutants
(HAPs) exposure as a contributing risk factor for LK. This
study aims to evaluate the level and the distribution of HAPs
and LK rate in Texas counties.
Methods: Incidence rate per counties was provided by the
Texas Cancer Registry. Total emission values (ev) in ton per
year (tpy) for 188 HAPs were monitored by US Environmen-
tal Protection Agency. Counties with zero LK incidence
(Gr0) versus counties with the highest LK incidence (over
10: Gr10) were compared.
Results: Mean age-adjusted LK incidence rate in Texas
(2002–2010) is 7.57 ± 2.58. Gr0 included 10 counties with
the presence of 80% (151/188) HAPs. Gr0 HAPs mean ev
was always below Gr10 mean ev (range 0–20 tpy). Gr10
included 15 counties with the presence of all 188 HAPs;
Gr10 HAPs mean ev was consistently higher compared to
Gr0 (over 100 tpy). In Gr10, ten counties were identified with
HAPs total ev greater than state HAPs mean ev. Specifically
9 HAPs classified as cancerogenic, were identified for
highest and significantly different ev (Table 1).
Conclusions: In Texas counties at higher level of HAPs
total ev corresponds a higher LK incidence rate. Our findings
suggest HAPs exposure as a potential additional factor to be
considered in the multifactorial liver carcinogenesis.
MO-A.14 (SIGMA-2/SMAC) IS A STRONG
ENHANCER OF GEMCITABINE
SENSITIVITY IN PANCREATIC
ADENOCARCINOMA
Y. Hashim1, D. Spitzer1, S. Vangveravong1,
P. Goedegebuure1, M. Hornick1, R. Mach2, W. Hawkins1
1Washington University School Of Medicine In St Louis,
Department Of Surgery, St Louis, MO; 2University Of
Pennsylvania, Department Of Radiochemistry,
Philadelphia, PA
Introduction: Gemcitabine remains a standard chemo-
therapy for pancreatic adenocarcinoma. Unfortunately the
response rate is 9.4% and OS is extended by a few months.
Second mitochondria-derived activator of caspases (SMAC)
kills cells by reversing the activity of IAPs and was shown to
increase pancreatic cancer sensitivity to Gemcitabine.
Sigma-2 receptors are highly expressed in pancreas cancer
cells. We developed a novel drug Sigma-SMAC (SW IV-134)
that can be delivered selectively to pancreatic cancers using
sigma-2 ligands and targeting IAPs pathway. This drug has
high potency with minimal toxic effects. Here we investi-
gated the combination of this targeted drug with Gemcitabine
to improve therapeutic response and minimize toxicity.
Methods: We tested sub-therapeutic doses of SW IV-134,
Gemcitabine, and the combination on pancreatic cancer cells
to test for synergy. Titer Glo viability, Caspases and annexin
assays were performed to compare the potency between the
drugs and their combination. Result: Viability assays showed
15% of the cells were alive after treatment with combination
Abstracts 87
© 2014 The Authors
HPB © 2014 Americas Hepato-Pancreato-Biliary AssociationHPB 2014, 16 (Suppl. 1), 1–99
therapy compared with 80% of cells treated by the single
compounds. Caspase levels were 2.5 fold the baseline in
combination therapy compared to 1.5 fold of single agent.
FACS for Annexin staining showed 27%, 15% and 5%
apoptotic cells treated with combination, Gemcitabin and
SW IV-134 respectively. P values for these tests were < 0.05.
Conclusion: We developed (SW IV-134) with promising
efficacy and minimal toxicity. It has strong synergetic effect
in combination with Gemcitabine. This strategy has a poten-
tial to improve chemotherapeutic efficacy, minimize toxicity
and benefit patients with pancreatic cancer.
MO-A.16 HIGH UTILIZATION OF LIVER
TRANSPLANTATION FOR
HEPATOCELLULAR CARCINOMA: IS IT
CONCERNING?
A. E. Alsina1, K. Vu4, J. Arrobas2, E. Franco1, N. Kemmer3,
G. W. Neff3, A. Valencia2 and S. Houston2
1Tampa General Hospital, Liver Transplantation Surgery,
Tampa, FL; 2Tampa General Hospital, Office Of Clinical
Research, Tampa, FL; 3Tampa General Hospital,
Transplant Hepatology, Tampa, FL; 4University Of South
Florida, Morsani College Of Medicine, Tampa, FL
Data regarding the utilization of liver transplantation (LTx)
for hepatocellular carcinoma (HCC) is limited by registry
studies. Updated studies are needed from experienced LTx
centers. We aimed to investigate the utilization of LTx for
HCC in the last 4 years. We hypothesize that the utilization at
this center is high, based on dedicated HCC program, MELD
scores and other factors.
Methods: The study comprised 353 consecutive HCC
patients referred and evaluated at our transplant and cancer
program between Jan. 2009 to Dec. 2012. Demographics,
tumor characteristics, and Barcelona Clinic staging were cal-
culated. Stage A and B patients were considered potentially
eligible for LTx.
Results: 23% of all HCC and 29% of eligible HCC received
LTx. Median Wait List Time was 35 days. Main reasons for
not referring were: tumor characteristics (76%) and progres-
sion (9%). Reasons for not listing were: comorbidities
(27%), tumor characteristics ( 25%), and financial/insurance
(12%).
Conclusion: Our center listed and transplanted nearly a
third of potentially eligible patients, based on stage. 23% of
all HCC patients were transplanted. This is the highest utili-
zation reported and a high benchmark, favoring HCC
patients. The rising incidence of HCC, MELD scores, and a
well organized liver cancer program contributed to this high
utilization. Of immediate concern is the detrimental effect of
this high utilization on patients with end stage liver disease
awaiting LTx. This requires further study. On the other hand,
the high utilization of HCC LTx in upcoming eras of hepatitis
C cure may not be undesirable.
MO-A.17 REOPERATION FOR BLEEDING
FOLLOWING LIVER
TRANSPLANTATION
D. A. DuBay, D. T. Redden, M. A. Thompson,
L. Glueckert, A. B. Smith, J. H. Crawford, K. A. Jones,
S. H. Gray, J. White and D. E. Eckhoff
University Of Alabama At Birmingham, Birmingham, AL
Introduction: This study’s objective was to identify risk
factors associated with liver transplantation (LTx) bleeding
requiring reoperation as well as the impact on mortality and
short-term clinical outcomes.
Methods: A retrospective study was performed to identify
risk factors associated with reoperation for bleeding follow-
ing LTx performed at a single institution between 2000–
2012. Operative reports were used to identify patients who
underwent reoperation for bleeding within 1 week following
LTx (operations for non-bleeding etiologies were excluded).
Results: Reoperation for bleeding was observed in 110/
1136 (9.7%) of LTx patients. The following characteristics
were associated with reoperation: recipient MELD score,
number of platelets transfused, and non-utilization of Amicar
(Table). Stratified by MELD score, the risk of reoperation for
bleeding was 4.4% (MELD ≤10), 7.9% (MELD 10–19),
12.3% (MELD 20–29) and 19.0% (MELD ≥30). Stratified by
units of platelets (plts) administered, the risk of reoperation
for bleeding was 13.5% (no plts), 10.6% (1 u plts), 9.6% (2 u
plts) and 6.5% (≥3 u plts). LTx patients who underwent
reoperation for bleeding had a longer ICU stay (5 days ± 7
vs. 2 days ± 3, p < 0.001) and hospitalization (18 days ± 9 vs.
10 days ± 18, p < 0.001). The risk of death increased in
patients who underwent reoperation for bleeding (HR 1.89,
95% CI 1.26, 2.85).
Conclusion: Reoperation for bleeding following LTx was
associated with increased resource utilization and recipient
mortality. A lower threshold for intraoperative platelet trans-
fusion and antifibrinolytics, especially in patients with high
lab-MELD score, may decrease the incidence of reoperation
for bleeding following LTx.
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MO-A.18 THE IMPACT OF
PRE-TRANSPLANT HOSPITALIZATION
ON POST-OPERATIVE LENGTH OF STAY
AND COST OF LIVER
TRANSPLANTATION
S. J. Knechtle, L. I. Brummett, C. Devroy,
R. Subramanian, A. B. Adams, J. Magliocca and J. Spivey
Emory University School Of Medicine, Atlanta, GA
Background: Pre-operative acuity impacts outcomes of
surgery and length of stay (LOS) although this has not been
systematically evaluated for liver transplantation (LT). We
used cost data to evaluate the impact of pre-transplant hos-
pitalization on length of post-operative hospitalization and
cost of initial hospital stay at this transplant center. Pre-
operative hospitalization was used as a surrogate for acuity.
Methods: Between December, 2009 and July, 2013, 368
consecutive adult deceased donor LT were performed in 354
patients. 26 combined organ transplants were excluded, 14
retransplants were excluded, and 3 for incomplete cost data.
For the remaining 325 LT, the data represent the total cost
incurred for treatment of patients between the transplant and
discharge from the hospital, excluding physician profes-
sional costs. The patients were divided into two groups:
patients transplanted from home and patients hospitalized
prior to LT.
Results: 93 patients were hospitalized at our center prior to
LT and 232 were admitted from home for their LT. The table
shows total cost and LOS for the two groups.
Conclusion: Pre-transplant hospital admission reflected
greater acuity of illness as reflected by almost twice as long
LOS and significantly higher charges. When bundled
payment methodology and accountable care organizations
consider LT reimbursement, acuity of illness substantially
influences LOS and cost of LT and will need to be considered
so as to not discourage care of sicker patients. The impact on
cost of additional measures of acuity such as MELD, ICU
stay pre-transplant, and BMI are also being evaluated at our
center.
MO-A.19 SURVIVAL OUTCOMES IN
LIVER TRANSPLANT RECIPIENTS WITH
MELD OF 40 AND HIGHER A DECADE
LONG EXPERIENCE
H. J. Panchal1, J. Patterson2, J. Durinka3 and J. Ortiz3
1Mount Sinai School Of Medicine, NY, NY; 2Lincoln
Medical And Mental Health Center, NY, NY; 3Albert
Einstein Healthcare Network, Philadelphia, PA
Introduction: The model for end-stage liver disease
(MELD) score has been used as a prioritizing and prognostic
tool since 2002, and has stabilized pre-transplant mortality.
However, the number of waitlisted candidates withdrawn
because they were too ill to be transplanted has doubled
between 2009 and 2011. The increasing proportion of trans-
plant candidates with a higher MELD score combined with
the improvement in transplant outcomes mandate the need to
study surgical outcomes in those patients with MELD score
of 40 or higher.
Methods: A retrospective analysis of all UNOS data on all
liver transplantations performed between February 2002 and
June 2011. Our primary outcomes of interest were graft and
patient survival at 1, 3, 12, 36, and 60-months.AKaplan Meier
Product limit method was used to determine survival rate.
Results: A total of 3848 transplant recipients were identified
based on MELD score with a median age of 51 years, 63.6%
of which were male. Graft survival at 1, 3, 12, 24, 36, and 60
months was 88.9%, 83.2%, 74.4%, 69.2%, 66.1%, and
61.4% respectively; patient survival was 90.6%, 85.6%,
77.9%, 73.1%, 70.2%, and 65.9% respectively. A multivari-
ate Cox regression analysis was done to identify significant
predictors of graft and patient survival. Donor and recipient
age, Hispanic and Asian ethnicity, diabetes, and ICU hospi-
talization at transplant were all identified as predictors of
graft and patient survival.
Conclusion: The results indicate that liver transplantation in
recipients with a MELD score of 40 or greater is promising
with significant survival after transplantation.
MO-A.20 THE USE OF VENOUS JUMP
GRAFTS IN PANCREAS
TRANSPLANTATION IS NOT
ASSOCIATED WITH INCREASED GRAFT
FAILURE OR MORTALITY
E. Siskind1, M. Akerman1, S. Ashburn1, E. Molmenti1,
A. Basu1 and J. Ortiz2
1North Shore Long Island Jewish Health System,
Manhasset, NY; 2Albert Einstein Medical Center,
Philadelphia, PA
Introduction: Pancreas transplantation is an established
treatment for patients with type 1 diabetes and renal failure or
life threatening glucose unawareness. The technical compo-
nents of the operation may vary by individual surgeon.
Venous jump grafts are used to salvage a pancreas with a
short portal vein or to facilitate an easier anastomosis. Early
reports indicated that the use of venous jump grafts led to an
increased risk of vascular thrombosis. There have been no
large reports evaluating the safety of venous jump grafts in
pancreas transplantation. We analyzed the UNOS database to
determine whether venous jump grafts are associated with
graft loss or patient death.
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Materials and methods: Data from UNOS on all adults pan-
creas or kidney pancreas transplant recipients between 1996 and
2012 were analyzed. Venous extension grafts were used in 2,657;
they were not used in 18,124. Chi square test was used to
compare many of the standard categorical variables. The Mann-
Whitney test was used to compare the two groups for continuous
variables. Kaplan-Meier/Product-Limit Estimates and their cor-
responding 95% confidence intervals were computed. One, 3, 5,
10 and 15 year unadjusted patient and graft survival rates were
computed for both groups.
Results: Kaplan -Meier analysis demonstrated similar
patient survival (p < 0.641) and death censored graft survival
(p < 0.351) at 1, 3, 5, 10 and 15 years between subjects with
and without venous jump grafts.
Conclusion: The use of venous jump grafts is NOT associ-
ated with a higher risk of graft loss or patient death.
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MO-B.01 IS CHROMOGRANIN A
PROGNOSTIC FOR RESECTED
PANCREATIC NEUROENDOCRINE
TUMORS?
M. A. Shanahan, C. S. Cho, P. A. Rudnitzky, G. Leverson,
E. R. Winslow and S. M. Weber
University Of Wisconsin School Of Medicine & Public
Health, Madison, WI
Introduction: Previous studies have suggested prognostic
potential for the tumor marker chromogranin A (CgA) for
pancreatic neuroendocrine tumors (pNETs), but results to
date have been controversial. Our purpose was to explore the
clinical usefulness of preoperative CgA in predicting
outcome in patients with resected pNETs.
Methods: Patients who underwent resection of a pNET
from 2002–2013 and had a CgA level tested within 3 months
before surgery were identified from a prospective database.
An elevated preoperative CgA was defined as a CgA lab
value above the normal limit of the assay.
Results: A total of 38 patients met inclusion criteria, of
which 16 patients (42%) had elevated preoperative CgA. Of
these, 45% were male and the median age was 57 years
(range, 17–81). Operations included: 13 pancreaticoduo-
denectomies, 22 distal pancreatectomies, 1 central pancrea-
tectomy and 2 enucleations. There were no differences in
tumor size, node positivity, margin status, or tumor grade
between the two groups on univariate analysis. Both disease-
free survival (p = 0.008) and overall survival (p = 0.05) were
negatively impacted by an elevated preoperative CgA level
(median FU for surviving patients, 2.5 years). The only inde-
pendent predictor of DFS on multivariate analysis was
elevated preoperative CgA (HR 9.36, 90% CI 1.60–54.7,
p = 0.037). There were no independent predictors of OS.
Conclusion: In patients with resected pNETs, an elevated
preoperative CgA level was associated with decreased
disease-free and overall survival, and remained the only inde-
pendent predictor of DFS. Preoperative CgA appears to be a
clinically useful prognostic marker following resection of
pNET.
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